In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
Michalina Janiszewska(Scripps Research Institute), Kornélia Polyák(Dana-Farber Cancer Institute), Ariella B. Hanker(Southwestern Medical Center), Britta Weigelt(Memorial Sloan Kettering Cancer Center), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Cloud P. Paweletz(Massachusetts General Hospital), Tari A. King(Brigham and Women's Hospital), Jorge S. Reis‐Filho(AstraZeneca (France)), Franziska Michor(Dana-Farber Cancer Institute), Lin Liu(Harvard University), So Yeon Park(Seoul National University Bundang Hospital), Yanan Kuang(Dana-Farber Cancer Institute), Rita A. Sakr(Memorial Sloan Kettering Cancer Center), Vanessa Almendro(Danaher (United States))
Cited by 166
Related Papers
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k